Paul Hammerness is a Psychiatry physician affiliated with Boston Medical Center. OpenAlex indexes 118 publications with 4,313 citations (h-index 39); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Boston Medical Ctr Pl
Boston, MA 021182908
Telephone
617-414-5245Provider last certified this registry record 18 Dec 2023.
Clinical trials
- Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
Sponsor: Massachusetts General Hospital
- Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD
Sponsor: Massachusetts General Hospital
- Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Central alpha-2 Adrenergic Agonist100%Clonidine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A randomized controlled trial of cognitive behavioral therapy for <scp>ADHD</scp> in medication‐treated adolescents
Journal of Child Psychology and Psychiatry
2016 - Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
Expert Opinion on Drug Safety
2015 - An Evidence-Based Systematic Review of Elderberry and Elderflower (<i>Sambucus nigra</i>) by the Natural Standard Research Collaboration
Journal of Dietary Supplements
2014
Similar KOLs
Other experts from the same institution or the same specialty.
Alice Jacobs, MD
Boston Medical Center
Carlos Kase, MD
Boston Medical Center
Sushrut Waikar, MD
Boston Medical Center
Geoffrey Oxnard, MD
Boston Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”